18 ANALYTICAL AND LABORATORY EQUIPMENT
Omega-3 manufacturers rise to their challenge
Excellent quality and multiple separation technologies are the key to success for omega-3 manufacturers, says Dr Peter Lembke.
W
ith 89,060 tonnes sold globally in 2013, and worth
US$1.76 billion, the global consumption of omega-3 fatty acids, in particular EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) concentrates is still a very fast growing market.
Te strongly expanding omega- 3-based pharma segment (including Lovaza, Omacor, Vascepa, Epadel and Epanova) and new-found consumer awareness is starting to focus more on higher concentrated omega-3 oils.
market. Recently, even higher concentrated EPA and/or DHA oils of up to well over 90% purity are used with growing popularity in the supplement and pharma field.
It is very likely that in a couple of years these highly concentrated omega-3 oils will dominate the global market due to the fact that they have a number of advantages for the consumer. Higher concentration means higher efficacy and improved health benefits.
Smaller and easier to swallow capsules can contain the same amount of omega-3 as the former large ‘horse pills’. Highly concentrated EPA or DHA products can be targeted at particular health issues and for improved prevention and therapeutic effects.
Te omega-3 manufacturing industry has to adjust to this trend. Simple molecular or short pass distillation technology, which was useful in the past to produce the medium concentrated 33/22 to 10/50 oils, has reached its limits.
Fig. 1. KD-Pharma runs a successful omega-3 manufacturing plant in Bexbach, Germany.
During the past few years a clear shift can be observed from the standard ‘18/12 fish oils’ (the first number refers to 18% EPA and the second to 12% DHA) towards higher concentrated and thus more efficient EPA and/or DHA concentrates.
Dr Peter Lembke is with KD-Pharma in Bexbach, Germany.
www.kd-pharma.com
www.scientistlive.com
Only a couple of years ago the first products containing 33/22 oils were introduced to the market, quickly substituting a significant portion of the standard fish oils. Ten higher concentrated oils such as 40/10, 10/40 and 10/50 entered the
Today and in the future, the requirements for a successful omega-3 manufacturer are far more challenging. With increasing concentration and purity, the manufacturing conditions shift from food/ supplement quality requirements into the much more stringent pharma GMP regulations.
Additionally, simple distillation units are no longer sufficient. Today a variety of separation technologies must be implemented by the manufacturer, including (but not
limited to) various distillation technologies, urea fractionation, liquid and/or supercritical fluid chromatography, selective extraction technology and enzymatic transformation.
Each technology has its own unique separation selectivity. A combination of these different separation selectivity factors coupled with a stringent quality assurance system is the key to future success in this increasingly competitive industry. A good example of this strategy can be seen at KD-Pharma Bexbach, a cGMP-certified German omega-3 manufacturer.
Te company not only developed two supercritical fluid technologies – supercritical fluid chromatography (SFC) and supercritical fluid extraction (SFE) – for the production of EPA and/or DHA concentrates, it also has a repertoire of other technologies that include distillation and urea fractionation.
As a result, the highest separation selectivity factors can be achieved via intelligent combinations of the abovementioned techniques.
Clients may also choose unique EPA DHA ratios or products manufactured only using the company’s gentle and proprietary SFC technology.
Specialising in one omega-3 manufacturing technology was sufficient to be successful in the past, but a now maturing market will push manufacturers for further technological sophistication and differentiation in the future.
For more information ✔ at
www.scientistlive.com/eurolab
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120